Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics

This article was originally published in The Pink Sheet Daily

Executive Summary

WuXiPharmaTech's biologics manufacturing site is expected to be fully operational in 2012.

You may also be interested in...

China's Pro-science Leaders To Make Biotech Drugs A Central Plank In New Five Year Plan

Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO

BEIJING - A New York-headquartered money management outfit that is the largest shareholder in Charles River Laboratories International has unexpectedly thrown up a potential blockade in the drug research firm's $1.6 billion proposal to acquire China's WuXi PharmaTech

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts